Address for correspondence: T. Jared Bunch, M.D., Intermountain Heart Rhythm Specialists, Intermountain Medical Center, Eccles Outpatient Care Center, 5169 Cottonwood Street, Suite 510, Murray, UT 84107, USA. Fax: 801-507-3584; E-mail: [email protected]

Dr. Day reports serving as a consultant for and/or on the advisory board of St. Jude Medical, and also receiving honoraria relevant to this topic from the company. He reports receiving research support from St. Jude Medical and Boston Scientific. No other authors declared any conflicts.

Read the full text

About

PDF

Tools

Share a link

Email
Wechat
Bluesky

Abstract

Background: The recently published HRS/EHRA/ECAS AF Ablation Consensus Statement recommended that warfarin should be used for at least 2 months following an AF ablation in all patients regardless of stroke risk factors. The objective of the study was to assess outcomes based upon anticoagulation practice after atrial fibrillation (AF) ablation to determine relative risk of a strategy of aspirin only in low-risk patients.

Methods: A total of 630 consecutive patients who underwent 934 ablation procedures using an open irrigated tip catheter for symptomatic AF were evaluated. Outcomes were compared between patients treated with warfarin (goal INR: 2–3) versus aspirin only (325 mg/day) in CHADS2 0–1 patients after ablation.

Results: Of the 690 patients, 123 (20%) were treated with aspirin and 507 (80%) with warfarin. Prevalences of the CHADS2 scores of patients on aspirin were (0: 40.7%, 1: 59.3%) and on warfarin (0: 13.6%, 1: 31.6%, ≥2: 54.8%), P < 0.0001. Patients in the warfarin group were older, had on average a lower ejection fraction, and had higher rates persistent/permanent AF, repeat ablations, hypertension, prior stroke/TIA, and diabetes. The 1-year survival free of AF for the total study population was 71.6%. There were no strokes/TIA in the aspirin group and 4 events (4 strokes, 0 TIAs) in the warfarin group. Two patients in the warfarin group died of fatal hemorrhage (1 intracranial, 1 gastrointestinal).

Conclusion: Select low-risk patients with a low CHADS2 (0–1) score who undergo left atrial ablation with an aggressive anticoagulation strategy with heparin and use of an open irrigated tip catheter with low CHADS2 scores can safely be discharged following their procedure on aspirin alone.

References

1 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
10.1056/NEJM199011293232201
CAS PubMed Web of Science® Google Scholar
2 Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991; 84: 527-539.
PubMed Web of Science® Google Scholar
3 Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-355.
10.1016/0735-1097(91)90585-W
CAS PubMed Web of Science® Google Scholar
4 Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
10.1056/NEJM199211123272002
CAS PubMed Web of Science® Google Scholar
5 Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic AF. The Copenhagen AFASAK study. Lancet 1989; 1: 175-179.
Web of Science® Google Scholar
6 Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE: Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700-705.
10.1016/j.amjmed.2006.07.034
PubMed Web of Science® Google Scholar
7 Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ: HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007; 4: 816-861.
10.1016/j.hrthm.2007.04.005
PubMed Web of Science® Google Scholar
8 Bunch TJ, Day JD: Novel ablative approach for atrial fibrillation to decrease risk of esophageal injury. Heart Rhythm 2008; 5: 624-627.
10.1016/j.hrthm.2007.11.007
PubMed Web of Science® Google Scholar
9 Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al : ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006; 48: e149-e246.
10.1016/j.jacc.2006.07.018
CAS PubMed Web of Science® Google Scholar
10 Hart RG, Benavente O, McBride R, Pearce LA: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation (a meta-analysis). Ann Intern Med 1999; 131: 492-501.
10.7326/0003-4819-131-7-199910050-00003
CAS PubMed Web of Science® Google Scholar
11 Dorwarth U, Fiek M, Remp T, Reithmann C, Dugas M, Steinbeck G, Hoffmann E: Radiofrequency catheter ablation: Different cooled and noncooled electrode systems induce specific lesion geometries and adverse effects profiles. Pacing Clin Electrophysiol 2003; 26: 1438-1445.
10.1046/j.1460-9592.2003.t01-1-00208.x
CAS PubMed Web of Science® Google Scholar
12 Ren JF, Marchlinski FE, Callans DJ, Gerstenfeld EP, Dixit S, Lin D, Nayak HM, Hsia HH: Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol 2005; 16: 474-477.
10.1046/j.1540-8167.2005.40465.x
PubMed Web of Science® Google Scholar
13 Wazni OM, Rossillo A, Marrouche NF, Saad EB, Martin DO, Bhargava M, Bash D, Beheiry S, Wexman M, Potenza D, Pisano E, Fanelli R, Bonso A, Themistoclakis S, Erciyes D, Saliba WI, Schweikert RA, Brachmann J, Raviele A, Natale A: Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: Impact of different anticoagulation regimens and importance of intracardiac echo imaging. J Cardiovasc Electrophysiol 2005; 16: 576-581.
10.1111/j.1540-8167.2005.40480.x
PubMed Web of Science® Google Scholar
14 Maleki K, Mohammadi R, Hart D, Cotiga D, Farhat N, Steinberg JS: Intracardiac ultrasound detection of thrombus on transseptal sheath: Incidence, treatment, and prevention. J Cardiovasc Electrophysiol 2005; 16: 561-565.
10.1111/j.1540-8167.2005.40686.x
CAS PubMed Web of Science® Google Scholar
15 Gerstenfeld EP, Jacobson J, Bazan V, Lazar S, Tomaszewski JE, Marchlinski FE, Michele J: Comparison of high power, medium power, and irrigated-tip ablation strategies for pulmonary vein isolation in a canine model. J Cardiovasc Electrophysiol 2007; 18: 849-853.
10.1111/j.1540-8167.2007.00869.x
PubMed Web of Science® Google Scholar
16 Nakagawa H, Yamanashi WS, Pitha JV, Arruda M, Wang X, Ohtomo K, Beckman KJ, McClelland JH, Lazzara R, Jackman WM: Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation 1995; 91: 2264-2273.
10.1046/j.1460-9592.2001.01261.x
CAS PubMed Web of Science® Google Scholar
17 Oral H, Chugh A, Ozaydin M, Good E, Fortino J, Sankaran S, Reich S, Igic P, Elmouchi D, Tschopp D, Wimmer A, Dey S, Crawford T, Pelosi F Jr, Jongnarangsin K, Bogun F, Morady F: Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006; 114: 759-765.
10.1161/CIRCULATIONAHA.106.641225
PubMed Web of Science® Google Scholar
18 Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004; 164: 880-884.
10.1001/archinte.164.8.880
CAS PubMed Web of Science® Google Scholar
19 McMahan DA, Smith DM, Carey MA, Zhou XH: Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 1998; 311-316.
10.1046/j.1525-1497.1998.00096.x
CAS PubMed Web of Science® Google Scholar
20 Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36: 1588-1593.
10.1161/01.STR.0000170642.39876.f2
PubMed Web of Science® Google Scholar
21 Bunch TJ, Nelson J, Foley T, Allison S, Crandall BG, Osborn JS, Weiss JP, Anderson JL, Nielsen P, Anderson L, Lappe DL, Day JD: Temporary esophageal stenting allows healing of esophageal perforations following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 2006; 17: 435-439.
10.1111/j.1540-8167.2006.00464.x
PubMed Web of Science® Google Scholar

Citing Literature

Volume20, Issue9

September 2009

Pages 988-993

Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Warfarin Is Not Needed in Low-Risk Patients Following Atrial Fibrillation Ablation Procedures

Abstract

References

Citing Literature

References

Related

Information